Kumar Rahul, Tiwari Vishvanath, Dey Sharmistha
Department of Biotechnology, GITAM Institute of Sciences, GITAM University, Visakhapatnam, India.
Department of Biochemistry, Central University of Rajasthan, Ajmer, India.
Eur J Neurosci. 2022 Nov;56(9):5442-5452. doi: 10.1111/ejn.15569. Epub 2022 Jan 17.
Alzheimer's disease (AD), a progressive neurodegenerative disorder, is the most common form of dementia in the elderly. Two major pathological hallmarks have been identified for AD: extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT). Recently, proline-rich tyrosine kinase 2 (Pyk2), which belongs to the focal adhesion kinase (FAK) non-receptor tyrosine kinase family, was recognized to contribute significantly towards the pathogenesis of AD. Pyk2 can influence the formation of amyloid plaques as well as NFTs. The kinase can directly phosphorylate tau, which is a significant component of NFTs and enhances tau pathology. Several competitive inhibitors have been developed for Pyk2, tested in several cancer models, as Pyk2 is known to be overexpressed under those conditions. The current review article discusses the possible mechanistic pathways by which Pyk2 can influence the pathogenesis of AD. Besides, it describes various inhibitors for Pyk2 and their potential role as therapeutics for AD in the future.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,是老年人中最常见的痴呆形式。已确定AD的两个主要病理特征:细胞外淀粉样斑块和细胞内神经原纤维缠结(NFT)。最近,富含脯氨酸的酪氨酸激酶2(Pyk2)属于粘着斑激酶(FAK)非受体酪氨酸激酶家族,被认为对AD的发病机制有重大影响。Pyk2可影响淀粉样斑块以及NFT的形成。该激酶可直接磷酸化tau,tau是NFT的重要组成部分,并增强tau病理。已经开发了几种针对Pyk2的竞争性抑制剂,并在几种癌症模型中进行了测试,因为已知Pyk2在这些情况下会过度表达。当前的综述文章讨论了Pyk2可能影响AD发病机制的途径。此外,它还描述了Pyk2的各种抑制剂及其未来作为AD治疗药物的潜在作用。